Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOYS8A)

Drug Name

PTG-300 Drug Info

Synonyms

Rusfertide; Rusfertide [USAN]; UNII-XM71MYX0IQ; XM71MYX0IQ; PTG-300FB; WHO 11456; 1628323-80-7; Isovaleryl-Asp-Thr-His-Phe-Pro-cyclo(Cys-Ile-Lys(palm-gamma-Glu)- Phe-Glu-Pro-Arg-Ser-Lys-Gly-Cys)-Lys-NH2

Indication

Disease Entry	ICD 11	Status	REF
Hemochromatosis	5C64.1Y	Phase 2	[1]
Polycythemia vera	2A20.4	Phase 2	[2]

Cross-matching ID

PubChem CID: 155884410
CAS Number: CAS 1628323-80-7
TTD Drug ID: DMOYS8A

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hepcidin (HAMP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NOX-H94	DM5HPZU	Anemia	3A00-3A9Z	Phase 2	[4]
LJPC-401	DMVM13R	Beta thalassemia	3A50.2	Phase 2	[5]
Hepcidin mab	DMBFYSR	Anemia	3A00-3A9Z	Phase 1	[6]
LY2787106	DM9NYHT	Anemia	3A00-3A9Z	Phase 1	[7]
12B9m	DM5IUN8	Anaemia	3A90	Preclinical	[8]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepcidin (HAMP)	TTPCG5T	HEPC_HUMAN	Replacement	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04202965) PTG-300 in Subjects With Hereditary Hemochromatosis. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT04767802) PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of Protagonist Therapeutics.
4	The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013 Mar 21;121(12):2311-5.
5	ClinicalTrials.gov (NCT03395704) A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis. U.S. National Institutes of Health.
6	The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161.
7	A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 Mar 21;10(1):73.
8	Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J. 2010 Dec;12(4):646-57.